Our results show that pyrvinium treatment confers therapeutic benefits on the metabolism of glucose and lipids in treatment of metabolic disorders through β-catenin downregulation as well as the unexpected AMPK activation. The gene discussed is PRKAA1; the disease is metabolic disease.